Susan M. Ascher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Susan M. Ascher has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Caroline Reinhold
2 shared publicationsReena C. Jha
2 shared publications- Alan Penn
Penn Diagnostics, 14 Clemson Ct, Rockville, MD 20850, USA
1 shared publication C Schlesinger
Department of Anatomic Pathology, City of Hope Medical Center, Duarte, California 91010-3000, USA
1 shared publicationCarla de Venecia
Department of Radiology, MedStar Georgetown University Medical Center, Washington, DC
1 shared publication- Constance D. Lehman
University of Washington and Seattle Cancer Care Alliance, Seattle, WA 98109, USA
1 shared publication
Latest Publications
- 1 August 2015
- Published by Elsevier in Seminars in Ultrasound, CT and MRI
- Vol. 36 (4) , 385-393
Pelvic Endometriosis: Spectrum of Magnetic Resonance Imaging Findings
- 1 August 2015
- Published by Elsevier in Seminars in Ultrasound, CT and MRI
- Vol. 36 (4) , 385-393
Pelvic Endometriosis: Spectrum of Magnetic Resonance Imaging Findings
- 1 November 2006
- Published by Elsevier in Academic Radiology
- Vol. 13 (11) , 1344-1354
Morphologic Blooming in Breast MRI as a Characterization of Margin for Discriminating Benign from Malignant Lesions
- 1 November 2006
- Published by Elsevier in Academic Radiology
- Vol. 13 (11) , 1344-1354
Morphologic Blooming in Breast MRI as a Characterization of Margin for Discriminating Benign from Malignant Lesions
- 1 August 2003
- Published by Wolters Kluwer Health in Topics in Magnetic Resonance Imaging
- Vol. 14 (4) , 281-304
Benign Myometrial Conditions: Leiomyomas and Adenomyosis
Leiomyomas and adenomyosis are common benign myometrial conditions. Although their symptoms overlap, traditional treatment of these two entities differs; thus, making the correct diagnosis is critical. Specifically, uterine-conserving therapy is well established for many women with symptomatic leiomyomas, whereas hysterectomy is the treatment for debilitating adenomyosis. Magnetic resonance imaging (MRI) is the most accurate modality for identifying leiomyomas and adenomyosis. T2-weighted sequences often are diagnostic. For leiomyomas, MRI reliably identifies their number, size, and location. These features help triage patients to appropriate therapy. For adenomyosis, MRI establishes the diagnosis in cases of equivocal or nondiagnostic ultrasounds. MRI also has been used to confirm an ultrasound diagnosis of adenomyosis when curative surgery is being considered. Intravenous gadolinium chelates are not necessary to make the diagnosis of either adenomyosis or leiomyomas, but it provides useful information about vascularity of lesions, a factor that may impact the type of treatment undertaken.
- 1 August 2003
- Published by Wolters Kluwer Health in Topics in Magnetic Resonance Imaging
- Vol. 14 (4) , 281-304
Benign Myometrial Conditions: Leiomyomas and Adenomyosis
Leiomyomas and adenomyosis are common benign myometrial conditions. Although their symptoms overlap, traditional treatment of these two entities differs; thus, making the correct diagnosis is critical. Specifically, uterine-conserving therapy is well established for many women with symptomatic leiomyomas, whereas hysterectomy is the treatment for debilitating adenomyosis. Magnetic resonance imaging (MRI) is the most accurate modality for identifying leiomyomas and adenomyosis. T2-weighted sequences often are diagnostic. For leiomyomas, MRI reliably identifies their number, size, and location. These features help triage patients to appropriate therapy. For adenomyosis, MRI establishes the diagnosis in cases of equivocal or nondiagnostic ultrasounds. MRI also has been used to confirm an ultrasound diagnosis of adenomyosis when curative surgery is being considered. Intravenous gadolinium chelates are not necessary to make the diagnosis of either adenomyosis or leiomyomas, but it provides useful information about vascularity of lesions, a factor that may impact the type of treatment undertaken.
- 1 May 2002
- Published by Elsevier in Radiologic Clinics of North America
- Vol. 40 (3) , 563-576
Imaging of cancer of the endometrium
- 1 May 2002
- Published by Elsevier in Radiologic Clinics of North America
- Vol. 40 (3) , 563-576
Imaging of cancer of the endometrium
- 1 April 2001
- Published by Wolters Kluwer Health in Topics in Magnetic Resonance Imaging
- Vol. 12 (2) , 105-129
Staging of Gynecologic Malignancies
Magnetic resonance imaging (MRI) is gaining momentum for staging gynecologic malignancies. MRI staging is an adjunct to clinical and surgical staging in women with cervical or endometrial cancer, respectively. For women with possible adnexal pathology, MRI is useful for lesion characterization. In patients with ovarian cancer, MRI determination of disease extent helps treatment planning, either as a surgical roadmap or to identify nonresectable patients.
- 1 April 2001
- Published by Wolters Kluwer Health in Topics in Magnetic Resonance Imaging
- Vol. 12 (2) , 105-129
Staging of Gynecologic Malignancies
Magnetic resonance imaging (MRI) is gaining momentum for staging gynecologic malignancies. MRI staging is an adjunct to clinical and surgical staging in women with cervical or endometrial cancer, respectively. For women with possible adnexal pathology, MRI is useful for lesion characterization. In patients with ovarian cancer, MRI determination of disease extent helps treatment planning, either as a surgical roadmap or to identify nonresectable patients.
- 1 January 2000
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 214 (1) , 29-38
Tamoxifen-induced Uterine Abnormalities: The Role of Imaging
Tamoxifen citrate is an orally administered, nonsteroidal antiestrogen agent that is widely used for the treatment of breast cancer and that has recently been found to prevent breast cancer in some high-risk populations. Tamoxifen may, however, cause adverse effects at the uterine level. In this article, the authors review (a) the histopathologic uterine changes associated with tamoxifen therapy, (b) the spectrum of uterine imaging findings in women treated with tamoxifen, and (c) the recommendations of the American College of Obstetrics and Gynecology for women treated with tamoxifen. An algorithm for imaging evaluation of the uterus in women treated with tamoxifen is presented.
- 1 January 2000
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 214 (1) , 29-38
Tamoxifen-induced Uterine Abnormalities: The Role of Imaging
Tamoxifen citrate is an orally administered, nonsteroidal antiestrogen agent that is widely used for the treatment of breast cancer and that has recently been found to prevent breast cancer in some high-risk populations. Tamoxifen may, however, cause adverse effects at the uterine level. In this article, the authors review (a) the histopathologic uterine changes associated with tamoxifen therapy, (b) the spectrum of uterine imaging findings in women treated with tamoxifen, and (c) the recommendations of the American College of Obstetrics and Gynecology for women treated with tamoxifen. An algorithm for imaging evaluation of the uterus in women treated with tamoxifen is presented.
- 1 October 1998
- Vol. 17 (4) , 302-11
Endometrial polyps: a comparison study of patients receiving tamoxifen with two control groups.
Many reports describe an increased frequency and unusual features of endometrial polyps and carcinomas in women treated with tamoxifen (TMX) for breast cancer. Postmenopausal women with endometrial polyps were identified by computer search of pathology files from 1990 to 1996. Medical records were reviewed, and patients were divided into three groups: 28 receiving TMX for breast cancer, 23 receiving hormone replacement therapy (HRT), and 28 untreated controls (UC). Cumulative doses (CDs) of TMX were calculated. Histologic slides of polyps were reviewed blindly and evaluated for size, metaplasias, vascularity, fibrosis, and inflammation. Carcinomas were found in 3 TMX, no HRT, and 1 UC patient. Atypical hyperplasias were found in 1 TMX, 0 HRT, and 1 UC patient. Mean polyp size was larger in the TMX group (2.9 cm) than in the HRT (1.05 cm) and UC (1.35 cm) groups, and stromal fibrosis was more prominent in TMX-related and larger polyps. Mucinous metaplasias were observed more frequently in the patients receiving TMX. No other differences were noted. The two TMX patients in whom low-grade carcinomas developed and the one with atypical hyperplasia had independent risk factors. CDs for these patients were 32.9, 36.5, and 17.6 g, respectively. A high-grade carcinoma developed in a TMX patient without constitutional risk factors at a CD of 94.9 g. On the basis of a literature review and these results, low-grade carcinomas developing after relatively low CDs of TMX may be at least partially attributable to other risk factors. The association between poorly differentiated and nonendometrioid tumors with higher TMX CDs is still speculative, but the current study suggests that they may be related to TMX. A statistically significant increase in the frequency of thyroid replacement use by TMX patients is also noted.
- 1 October 1998
- Vol. 17 (4) , 302-11
Endometrial polyps: a comparison study of patients receiving tamoxifen with two control groups.
Many reports describe an increased frequency and unusual features of endometrial polyps and carcinomas in women treated with tamoxifen (TMX) for breast cancer. Postmenopausal women with endometrial polyps were identified by computer search of pathology files from 1990 to 1996. Medical records were reviewed, and patients were divided into three groups: 28 receiving TMX for breast cancer, 23 receiving hormone replacement therapy (HRT), and 28 untreated controls (UC). Cumulative doses (CDs) of TMX were calculated. Histologic slides of polyps were reviewed blindly and evaluated for size, metaplasias, vascularity, fibrosis, and inflammation. Carcinomas were found in 3 TMX, no HRT, and 1 UC patient. Atypical hyperplasias were found in 1 TMX, 0 HRT, and 1 UC patient. Mean polyp size was larger in the TMX group (2.9 cm) than in the HRT (1.05 cm) and UC (1.35 cm) groups, and stromal fibrosis was more prominent in TMX-related and larger polyps. Mucinous metaplasias were observed more frequently in the patients receiving TMX. No other differences were noted. The two TMX patients in whom low-grade carcinomas developed and the one with atypical hyperplasia had independent risk factors. CDs for these patients were 32.9, 36.5, and 17.6 g, respectively. A high-grade carcinoma developed in a TMX patient without constitutional risk factors at a CD of 94.9 g. On the basis of a literature review and these results, low-grade carcinomas developing after relatively low CDs of TMX may be at least partially attributable to other risk factors. The association between poorly differentiated and nonendometrioid tumors with higher TMX CDs is still speculative, but the current study suggests that they may be related to TMX. A statistically significant increase in the frequency of thyroid replacement use by TMX patients is also noted.